The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
A Placebo-Controlled Randomized Trial of Warfarin in Idiopathic Pulmonary Fibrosis
Open accessAbstract
Rationale: Animal and human studies support the importance of the coagulation cascade in pulmonary fibrosis. Objectives: In a cohort of subjects with progressive idiopathic pulmonary fibrosis (IPF), we tested the hypothesis that treatment with warfarin at recognized therapeutic doses would reduce rates of mortality, hospitalization, and declines in FVC. Methods: This was a double-blind, randomized, placebo-controlled trial of warfarin targeting an international normalized ratio of 2.0 to 3.0 in patients with IPF. Subjects were randomized in a 1:1 ratio to warfarin or matching placebo for a planned treatment period of 48 weeks. International normalized ratios were monitored using encrypted home point-of-care devices that allowed blinding of study therapy. Measurements and Main Results: The primary outcome measure was the composite outcome of time to death, hospitalization (nonbleeding, nonelective), or a 10% or greater absolute decline in FVC. Due to a low probability of benefit and an increase in mortality observed in the subjects randomized to warfarin (14 warfarin versus 3 placebo deaths; P = 0.005) an independent Data and Safety Monitoring Board recommended stopping the study after 145 of the planned 256 subjects were enrolled (72 warfarin, 73 placebo). The mean follow-up was 28 weeks. Conclusions: This study did not show a benefit for warfarin in the treatment of patients with progressive IPF. Treatment with warfarin was associated with an increased risk of mortality in an IPF population who lacked other indications for anticoagulation. Clinical trial registered with www.clinicaltrials.gov (NCT00957242).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“This study found that among IPF patients on the standard therapy of the time (prednisone and azathioprine), the addition of high dose acetylcysteine preserved vital capacity (VC) and carbon monoxide diffusion capacity (DLCO) compared to placebo [61].”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [61]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
Self-citationIdiopathic Pulmonary Fibrosis: Diagnosis and Treatment: International Consensus Statement
(2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.161.2.ats3-00 · Cited by 2,628
A Method to Determine the Optimal Intensity of Oral Anticoagulant Therapy
Rosendaal, F. R., Cannegieter, S. C., van der Meer, F. J. M., & Briët, E. (1993) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1651587 · Cited by 2,065 · cited 1×
“Efficacy of home INR measures was determined by time-in-target INR range of all patients, calculated on the basis of linear interpolation (12), after excluding readings taken at baseline, during initial warfarin titration (until INR > 2.”
MethodEditorial: Cerebral Palsy—the International Consensus Statement
Clements, R. V., & Simanowitz, A. (2000) · Clinical Risk · doi:10.1177/135626220000600401 · Cited by 856
Predicting Survival in Idiopathic Pulmonary Fibrosis
KING, T. E., TOOZE, J. A., SCHWARZ, M. I., BROWN, K. R., & CHERNIACK, R. M. (2001) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.164.7.2003140 · Cited by 853 · cited 1×
“The median survival of patients with IPF after the onset of symptoms is 2 to 5 years (3).”
Backgroundinternational consensus statement
Clements, R. V., & Simanowitz, A. (2000) · Cited by 852
Idiopathic Pulmonary Fibrosis: Relationship between Histopathologic Features and Mortality
KING, T. E., SCHWARZ, M. I., BROWN, K., TOOZE, J. A., COLBY, T. V., WALDRON, J. A., FLINT, A., THURLBECK, W., & CHERNIACK, R. M. (2001) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.164.6.2001056 · Cited by 628
Interstitial Lung Disease: A Quantitative Study Using the Adaptive Multiple Feature Method
UPPALURI, R., HOFFMAN, E. A., SONKA, M., HUNNINGHAKE, G. W., & McLENNAN, G. (1999) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.159.2.9707145 · Cited by 564
Incidence, Prevalence, and Clinical Course of Idiopathic Pulmonary Fibrosis
Fernández Pérez, E. R., Daniels, C. E., St. Sauver, J., Hartman, T. E., Bartholmai, B. J., Yi, E. S., Ryu, J. H., & Schroeder, D. R. (2010) · Chest · doi:10.1378/chest.09-1002 · Cited by 509 · cited 2×
“Progressive IPF was defined as a history of (1) worsening of dyspnea, or (2) physiologic deterioration defined as an absolute decline of either FVC greater than or equal to 10% or DLCO greater than or equal to 15%, a reduction in arterial oxygen saturation of greater than or equal to 5%, or progression of radiographic…”
BackgroundAnticoagulant Therapy for Idiopathic Pulmonary Fibrosis
Kubo, H., Nakayama, K., Yanai, M., Suzuki, T., Yamaya, M., Watanabe, M., & Sasaki, H. (2005) · Chest · doi:10.1378/chest.128.3.1475 · Cited by 440 · cited 2×
“In contrast to our findings, a prior smaller study demonstrated a significant survival benefit for anticoagulation with prednisolone compared with prednisolone alone in patients with IPF (10).”
BackgroundResult
Research works printed but not linked: 1
- de Andrade, 2011, Hemostasis and fibrinolysis in the pathogenesis of lung injury and repair, 315
Cited by
Lederer, D. J., & Martinez, F. J. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1705751 · Cited by 2,056
Richeldi, L., Collard, H. R., & Jones, M. G. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30866-8 · Cited by 2,020
Raghu, G., Rochwerg, B., Zhang, Y., Garcia, C. A. C., Azuma, A., Behr, J., Brozek, J. L., Collard, H. R., Cunningham, W., Homma, S., et al. (2015) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201506-1063st · Cited by 1,916
Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report
Collard, H. R., Ryerson, C. J., Corte, T. J., Jenkins, G., Kondoh, Y., Lederer, D. J., Lee, J. S., Maher, T. M., Wells, A. U., Antoniou, K. M., et al. (2016) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201604-0801ci · Cited by 1,444
Self-citationMartinez, F. J., Collard, H. R., Pardo, A., Raghu, G., Richeldi, L., Selman, M., Swigris, J. J., Taniguchi, H., & Wells, A. U. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.74 · Cited by 1,388
Metadata
- Authors
- Noth, I., Anstrom, K. J., Calvert, S. B., de Andrade, J., Flaherty, K. R., Glazer, C., Kaner, R. J., & Olman, M. A.
- Affiliations
- University of Chicago (US)
- Duke University (US)
- University of Alabama, Birmingham, Alabama
- National Jewish Health (US)
- The University of Texas Southwestern Medical Center (US)
- Cornell University (US)
- Cleveland Clinic (US)
- Corresponding author
- Noth, Imre
- Venue
- American Journal of Respiratory and Critical Care Medicine
- Publisher
- Oxford University Press (OUP)
- Published
- 2012-07-01
- Volume
- 186
- Issue
- 1
- Pages
- 88-95
- ISSN
- 1073-449X (ISSN-L)
- 1535-4970
- PMC
- PMC3400994
- OpenAlex
- W2055609841
- Cited by
- 463
- References
- 22
- Citations by year
- 2026: 4 · 2025: 14 · 2024: 16 · 2023: 16 · 2022: 26 · 2021: 28 · 2020: 30 · 2019: 27 · 2018: 30 · 2017: 49 · 2016: 49 · 2015: 56 · 2014: 37 · 2013: 57 · 2012: 20
- FWCI
- 43.81
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- American Journal of Respiratory and Critical Care Medicine (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Chicago Community Trust
- National Heart, Lung, and Blood Institute (U10HL080509, U10HL080543, U10HL080571, U10HL080383, K24HL111316, U10HL080513, U10HL080685, U10HL080510, U10HL080413, U10HL080370, U10HL080411, U10HL080274, U10HL080371)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- idiopathic pulmonary fibrosis, warfarin, anticoagulation, coagulation cascade, mortality, hospitalization, forced vital capacity decline, international normalized ratio, blinding, early trial termination
- MeSH terms
- Adult, Aged, Aged, 80 and over, Anticoagulants, Double-Blind Method, Female, Hospitalization, Humans, Male, Middle Aged, Warfarin, Treatment Failure, International Normalized Ratio, Idiopathic Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Placebo-Controlled Randomized Trial of Warfarin in Idiopathic Pulmonary Fibrosis. https://app.cochat.ai/papers/10.1164/rccm.201202-0314oc
- The paper
- Noth, I., Anstrom, K. J., Calvert, S. B., de Andrade, J., Flaherty, K. R., Glazer, C., Kaner, R. J., & Olman, M. A. (2012). A Placebo-Controlled Randomized Trial of Warfarin in Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine. https://doi.org/10.1164/rccm.201202-0314oc
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.